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ABSTRACT Megakaryocyte-specific expression of the
platelet-adhesion receptor, integrin aIIbb3, is caused by the
presence of regulatory elements of the aIIb promoter that
direct high-level, selective gene transcription early in
megakaryocytopoiesis. To develop methods for targeted ex-
pression of transgenes, we transduced human CD341 periph-
eral blood cells with a murine leukemia virus (MuLV) vector
controlled by the human integrin aIIb promoter (nucleotides
2889 to 135). A naturally occurring cDNA encoding the PlA2
alloantigen form (Pro33) of the integrin b3 subunit was
subcloned into this construct (2889PlA2b3) and transduced
into cells that endogenously synthesized PlA1b3 (Leu33) as a
marker for detection of provirus-derived b3. The ability of this
vector to target expression of PlA2b3 to megakaryocytes was
first examined in cell lines. Immunoblot analysis with human
anti-PlA2 alloserum detected synthesis of PlA2b3 in trans-
duced promegakaryocytic cells; however, PlA2b3 protein was
not detected in transduced epithelial cells. Human hemato-
poietic CD341 cells were transduced with 2889PlA2b3 virions
and induced to differentiate with megakaryocyte growth and
development factor. A hybrid aIIbb3 complex was formed in
progeny megakaryocytes where provirus-derived PlA2b3 was
detected associated with endogenous aIIb subunit. Another
aIIb promoter-driven MuLV vector (2889nlacZ) encoding
Escherichia coli b-galactosidase was used to demonstrate that
transgene expression was selectively targeted to the
megakaryocyte progeny of transduced CD341 cells. These
studies demonstrate the feasibility of using aIIb promoter-
driven MuLV vectors for gene transfer of hematopoietic
CD341 cells to target transgene expression in developing
megakaryocytes and platelets and indicate potential applica-
tions toward human gene therapy for platelet disorders.
During megakaryocytopoiesis, pluripotent hematopoietic pro-
genitor and precursor cells differentiate to mature polyploid
megakaryocytes that shed small anucleate platelets. This pro-
cess is associated with three remarkable cellular events. First,
megakaryocyte-specific adhesion receptors are expressed,
namely integrin aIIbb3 and the glycoprotein Ib-V–IX com-
plex, which mediate platelet–platelet and platelet–extracellu-
lar matrix interactions. Second, cytoplasmic granules are
formed that contain agonists, hemostatic mediators, and
growth factors. Third, signaling pathways develop that produce
cyclic nucleotides, inositol phosphates, and endoperoxides,
which induce release of granule components and activation of
membrane receptors. Interactions between membrane recep-
tors, cytoplasmic granules, and signaling pathways induce
platelets to bind to adhesive proteins exposed on damaged
blood vessels, complex with plasma components, mediate
blood coagulation, and release granule contents. This regu-
lates blood clotting, stimulates wound healing, and mediates
platelet aggregation to seal damaged vessels.
Megakaryocyte-specific expression of the major platelet-
aggregation receptor, integrin aIIbb3, is caused by the pres-
ence of regulatory elements of the aIIb promoter that direct
high-level, selective gene transcription early in megakaryocy-
topoiesis. The aIIb promoter has been previously demon-
strated to direct high-level, megakaryocyte-targeted gene tran-
scription in human cell lines (1–3), rat cells (4), and transgenic
mice (5, 6). An 800-nt fragment of the human aIIb promoter
directed expression of the thymidine kinase gene in a
megakaryocyte-selective manner in the transgenic mice stud-
ies (5, 6). This promoter fragment binds GATA and Ets factors
to induce a high level of gene transcription (7), which is
restricted to developing megakaryocytes because of an ele-
ment localized to the immediate 59 upstream region of the aIIb
gene between nucleotides 280 and 2130 (2–4).
This investigation uses murine leukemia virus (MuLV)-
derived vectors driven by an 889-nt fragment of the promoter
of the human aIIb gene to induce early and specific transgene
expression during megakaryocytopoiesis of human cells. Hu-
man CD341 hematopoietic cells transduced with MuLV-
derived vectors encoding either b3 or b-galactosidase (b-gal)
demonstrated lineage-specific transgene expression after dif-
ferentiation along a megakaryocytic pathway (8). The platelet
alloantigen 2 (PlA2) form of the integrin b3 subunit was used
to distinguish provirus-derived protein from endogenous pro-
tein in cultured megakaryocytes. This result demonstrates the
feasibility of lineage-specific gene expression in pluripotent
hematopoietic stem cells and has implications for human gene
therapy of hematopoietic disorders.
MATERIALS AND METHODS
Antibodies. Monoclonal antibody AP3 (9) and polyclonal
antibodies specific for b3 were from Peter J. Newman (Blood
Research Institute, Milwaukee, WI). Human anti-PlA2 b3
alloserum was from Brian Curtis (Blood Center of Southeast-
ern Wisconsin, Milwaukee, WI). Monoclonal antibody AP2
(10), which recognizes the aIIbb3 complex was from Robert R.
Montgomery (Blood Research Institute, Milwaukee, WI). A
monoclonal antibody that recognizes the erythrocyte-specific
protein, glycophorin A (GPA), was from Sigma.
Cell Lines. Dami and human 293 cell lines were from the
American Type Culture Collection. CFT1 cells were previously
described (11).
aIIb Promoter. Genomic DNA was isolated from the human
promegakaryocyte cell line, Dami, and a fragment of the
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human aIIb gene promoter was amplified by PCR using sense
primer ‘‘2889’’ (59-TTACGCGTCGACAGATCTGTGCT-
CAATGCTGTGCC-39) from nucleotide 2889 to 2872 (bold-
face) of aIIb and antisense primer (59-ATAGTTTAGCGGC-
CGCGCTCGCATCTTCCTTCTTCCAC-39) encoding nucle-
otides 132 to 122 of b3 and nucleotides 135 to 119 of aIIb.
The antisense primer positions the aIIb promoter in-frame
with the translation start site of b3. An aIIb promoter used for
b-gal gene transcription was constructed with the 2889 primer
and antisense primer (59-ATTATTGGGCCCCATCTTCCT-
TCTTCCAC-39) encoding nucleotides 14048 to 14058 of
b-gal in pCMVnlac (12) and nucleotides 135 to 119 of aIIb.
PCR products were cloned into plasmid vectors pGL3 or
pGEM-7zf (1) (Promega), and sequence was confirmed by
nucleotide analysis (13).
Retroviral Constructs. p-889PlA2b3. The 2889 aIIb pro-
moter for b3 expression was cloned 59 of cDNA encoding the
platelet alloantigen 2 (PlA2) form of b3 (14) (from Peter J.
Newman) within Bluescript plasmid vector (Stratagene).
Briefly, PlA2b3 cDNA in Bluescript was treated with restriction
enzymes (NotI, NsiI, and SalI), and a three-way ligation was
performed to join the NotI and SalI aIIb promoter fragment
and the two PlA2b3-Bluescript fragments. The 2889PlA2b3
DNA cassette (Fig. 1) was removed from Bluescript by treat-
ment with XbaI and ligated between the long terminal repeats
(LTR) of the MuLV-derived retroviral vector, pHIT-SIN, to
construct p2889PlA2b3. pHIT-SIN was derived from vector,
pS3, which encodes a 39-LTR sequence (from Estuardo Agui-
lar-Cordova, Baylor College of Medicine, Houston, TX) (15)
lacking the viral enhancer/promoter so that the aIIb promoter
could direct gene transcription.
p2889nLacZ. The 2889 aIIb promoter for b-gal was cloned
into plasmid vector, pCMVnlac (12) (from Jeffrey S. Bartlett,
University of North Carolina, Chapel Hill, NC), encoding
Escherichia coli b-gal. Briefly, pCMVnlac was treated with
restriction enzymes (ApaI and SalI), and the aIIb promoter
(treated with enzymes ApaI and SalI) was inserted 59 to cDNA
encoding b-gal. The 2889nLacZ cDNA cassette was removed
from pCMVnlac by treatment with BglII and NaeI and ligated
between the LTRs of pHIT-SIN to construct p2889nLacZ.
The sequence of p2889nLacZ was confirmed by nucleotide
analysis.
pCMVnLacZ. pCMVnLacZ was constructed when a cassette
encoding the cytomegalovirus (CMV) immediate early pro-
moter and enhancer region and E. coli b-gal was removed from
pCMVnlac with restriction enzymes (NaeI and SamI) and
inserted between the LTRs of pHIT-SIN.
Retroviral Helper Plasmids. Plasmids pCI-GPZ and pCI-
VSV-G were previously described (16).
Typing of PlA Alloantigen. All cell samples used for
2889PlA2b3 transduction were confirmed homozygous for the
PlA1b3 alloantigen as described (17).
Retrovirus Production. Human 293 cells were transiently
transfected on 10-cm plates with 15 mg each of pCI-GPZ,
pCI-VSV-G, and either p2889PlA2b3, p2889nLacZ, or pC-
MVnLacZ by using the calcium transfection system (Life
Technologies, Gaithersburg, MD). After 12 h, cells were
placed in fresh medium containing 10 mM n-butyric acid
(Sigma) (18), and incubation continued at 37°C for 24 h.
Virions were concentrated 500-fold, resuspended in Iscove’s
modified Dulbecco’s Eagle’s medium (IMDM), and stored at
280°C. Replication-competent virions were confirmed absent
from viral preparations by using extended marker rescue assays
as described (18).
Selection of CD341 Cells. Peripheral blood cells were
collected after obtaining written informed consent from nor-
mal healthy subjects enrolled in an Institutional Review Board-
approved study. Subjects were given granulocyte colony-
stimulating factor (Amgen Biologicals) at 10 mgzkg21zd21
subcutaneously for days 1–5, and peripheral blood cell collec-
tion was performed on days 5 and 6 by using the CS-3000 Plus
cell separator (Baxter Diagnostics, McGaw Park, IL). CD34
antigen-positive cells were immunoselected (89% CD341
purity) from the apheresis product on an Isolex 300i magnetic
cell separator (Nexell Therapeutics, Irvine, CA, distributed
through Baxter Health Care, Mundelein, IL) as described (19).
Selected cells were suspended in X-Vivo 10 (BioWhittaker)
containing 1% (wt/vol) human serum albumin, frozen in 10%
(vol/vol) DMSO at 5–10 3 106 cells per ml, and stored in liquid
nitrogen.
Transduction of Human Cell Lines. Dami and CFT1 cells
(2.5 3 105) were transduced with 500 ml of 2889PlA2b3
retroviral supernatant titered at approximately 1 3 106 infec-
tious units/ml in the presence of 8 mg/ml polybrene (Sigma) in
one well of a six-well plate at 37°C in 5% CO2. After 2.5 h,
retroviral supernatant was removed, and fresh medium was
added. Twenty-six days after transduction, 7.0 3 106 cells were
lysed from each sample, and 800 mg of each lysate (BCA
protein assay, Pierce) was subjected to immunoprecipitation
analysis.
Transduction of CD341 Cells. Human CD341 cells were
transduced by a modified version of a previously described
protocol (20). Briefly, cells were maintained in Iscove’s mod-
ified Dulbecco’s Eagle’s medium containing 20% FBS, 10
units/ml recombinant human (rh) IL-3, 100 units/ml rhIL-6, 30
units/ml recombinant murine stem cell factor (Genetics Insti-
tute, Cambridge, MA) and 10 ng/ml flk2/f lt3 ligand (R&D
Systems) for 48 h at 37°C in 5% CO2. Cells were transduced at
1 3 105 cells per well of a sterile, 24-well non-tissue culture-
treated plate (Falcon-Becton Dickinson) coated with 20 mg/
cm2 RetroNectin (21, 22) (Takara Shuzo, Otsu, Japan) with an
estimated virion titer of 1 3 106 infectious units/ml
(2889PlA2b3, 2889nLacZ, or CMVnLacZ) in Iscove’s mod-
ified Dulbecco’s Eagle’s medium plus 20% FCS and rhIL-3,
rhIL-6, recombinant murine stem cell factor, and flk2/f lt3
ligand. Viral supernatant was removed and fresh supernatant
added after 2, 4, and 6 h. This procedure was repeated after
24 h. Twenty-four hours after the final transduction,
megakaryocyte formation was induced similar to a described
method (8). Cells were resuspended at 2.5 3 105 per ml in
FIG. 1. Schematic diagram of the retroviral plasmid constructs.
Transgene cassettes were inserted between the LTR-containing ele-
ments (U3, R, U5) of a MuLV-derived vector. The MuLV enhancer
region was deleted from a sequence (U3) of the 39 LTR (15), and the
aIIb promoter (nucleotides 2889 to 135) was used to direct expres-
sion of the PlA2b3 or b-gal (nLacZ) in transduced cells. This aIIb
promoter segment contains sequences necessary for megakaryocyte-
specific expression (7). The immediate-early enhancer/promoter re-
gion of the CMV drives gene transcription for retroviral production in
the 293 cells (see Materials and Methods). As a positive control, the
CMV promoter was used to drive nonspecific expression of b-gal in
cells transduced with virions produced from vector pCMVnLacZ.






















Iscove’s modified Dulbecco’s Eagle’s medium containing 10%
platelet-poor plasma and recombinant human IL (rhIL)-3,
rhIL-6, recombinant murine stem cell factor, and flk2/f lt3
ligand plus 100 ng/ml rhIL-11 (Genetics Institute) and 100
ng/ml recombinant human megakaryocyte growth and devel-
opment factor (23) (Amgen Biologicals) for up to 17 days. Cells
were solubilized in 1 ml of lysis buffer and stored at 280°C.
Immunoprecipitation Analysis. Immunoprecipitation anal-
ysis was performed as described (24). Precleared lysates were
immunoprecipitated for 1 h at 25°C with either AP2 or AP3
coupled to Affi-gel Hz (Bio-Rad). Immunoprecipitates were
electrophoresed on a SDS/PAGE gel under nonreducing con-
ditions, and proteins were transferred to Immobilon-P (Mil-
lipore) and blocked in 10% FBS in Tris-buffered saline/Tween.
Immunoblots were analyzed with human anti-PlA2 alloimmune
serum (1:1,000 dilution) and a peroxidase-conjugated F(ab9)2
fragment donkey anti-human IgG (H1L) (Jackson Immu-
noResearch) at 1:20,000 dilution followed by detection by
chemiluminescence. Some membranes were stripped by incu-
bation in buffer (100 mM 2-mercaptoethanol/2% SDS/62.5
mM TriszHCl, pH 6.7) at 50°C for 15 min, reblocked for 1 h,
and reprobed with a rabbit polyclonal antibody specific for b3
(4 mg/ml) and a peroxidase-conjugated F(ab9)2 fragment don-
key anti-rabbit IgG (H1L) (Jackson ImmunoResearch) at
1:20,000 dilution followed by chemiluminescence detection.
Indirect Immunofluorescence and Histochemical Staining.
Indirect immunofluorescence analysis was performed after 10
days of cytokine treatment to CD341 cells transduced with
2889nLacZ, CMVnLacZ, and untransduced cells. Cells (5 3
105) were blocked for 15 min in 2% BSA in PBS and incubated
with 5 mg of AP2 or anti-GPA for 20 min at 25°C and then were
treated with phycoerythrin-conjugated F(ab9)2 donkey anti-
mouse secondary antibody (Jackson ImmunoResearch) for 20
min on ice. Cells were resuspended in 200 ml of 2% formal-
dehyde and 0.2% gluteraldehyde in PBS and fixed to single
wells of a 24-well plate for 15 min at 25°C while centrifuging
at 230 3 g. Positive-staining cells were detected and photo-
graphed with a Zeiss Axiovert 10 fluorescence microscope at
3320 magnification. Histochemical staining of cells for b-gal
activity was performed as described (12). Cells were photo-
graphed a second time, and staining results were tabulated.
RESULTS
Effect of Viral LTR on aIIb Promoter-Targeted Transgene
Expression. Previous studies have demonstrated a small region
of the aIIb promoter sequence (1.2 kilobase) extending from
nucleotide 2813 to 133 to control megakaryocyte-specific
transgene expression in transfected cell lines (7, 25). To
construct a retroviral vector with potential to direct
megakaryocyte-targeted gene expression, the 59 region of the
human aIIb gene was amplified by PCR from nucleotide 2889
to 135 (2889) by using genomic DNA from a promegakaryo-
cyte cell line (Dami) and inserted between the LTR of a
MuLV-derived vector (pHIT-SIN) lacking the 39-viral enhanc-
er/promoter. Integrin b3 cDNA was subcloned 39 of the aIIb
promoter to construct plasmid p2889PlA2b3 (Fig. 1), and
2889PlA2b3 virions were produced and confirmed replication-
incompetent (see Materials and Methods). A rare form of b3
cDNA encoding a single amino acid substitution (Leu33 3
Pro33) that is recognized as the PlA2 alloantigen of b3 was used
as a marker of transgene expression. This allowed the use of
human alloimmune serum to distinguish the provirus-derived
PlA2 (Pro33) form of b3 in cells that endogenously synthesized
the PlA1 (Leu33) form of b3.
A promegakaryocyte cell line (Dami) and an epithelial cell
line (CFT1) were first transduced with 2889PlA2b3 virions to
determine whether viral LTR sequences adversely affect the
ability of the aIIb promoter to target gene expression to cells
where the endogenous aIIb promoter is active. Dami and
CFT1 cells were chosen because they transduce with equally
high efficiency by using a MuLV-derived vector, HIT-LZ (16),
encoding the E. coli b-gal gene (LacZ) (D.A.W. and G.C.W.,
unpublished observation). On day 26 posttransduction, provi-
ral DNA was detected by PCR analysis in 2889PlA2b3-
transduced Dami and CFT1 cells (data not shown). Immuno-
blot analysis was performed to determine whether PlA2b3 was
synthesized in Dami and CFT1 cells transduced with
2889PlA2b3. Cellular lysates were immunoprecipitated with a
b3-specific monoclonal antibody (AP3) and provirus-derived
b3 was detected with human anti-PlA2 alloimmune serum (Fig.
2). PlA2b3 was present in the 2889PlA2b3-transduced pro-
megakaryocyte cell line (Dami) but was not detected in
2889PlA2b3-transduced epithelial cells (CFT1)or LacZ-
transduced and -untransduced (control) cells. In addition,
PlA2b3 was not detected after 2889PlA2b3 transduction of a
lymphoblastic cell line (Raji) (data not shown). These results
indicate that viral LTR sequences do not adversely affect the
ability of the aIIb promoter to direct transgene expression in
a tissue-specific manner. The additional band appearing in Fig.
2 at 97 kDa on the control and transduced immunoblots is
likely nonspecific background resulting from chemiluminence
detection using AP3 and human sera.
aIIb Promoter-Directed Expression of PlA 2b3 in
Megakaryocytes Derived from Human CD341 Hematopoietic
Cells. To determine whether the aIIb promoter could target
transgene expression to primary megakaryocytes, 2889PlA2b3
virions were transduced into mobilized, peripheral blood
CD341 cells from individuals homozygous for the PlA1 form
of b3. The transduced cells were expanded in vitro and induced
to undergo megakaryocyte differentiation with IL-3, IL-6,
IL-11, recombinant murine stem cell factor, and megakaryo-
cyte growth and development factor. After 17 days, the
megakaryocyte-specific aIIbb3 receptor was immunoprecipi-
tated from cellular lysates with a complex-specific antibody
(AP2), and provirus-derived b3 was detected with human
alloimmune serum specific for the PlA2 form of b3. As shown
in Fig. 3 Upper, PlA2b3 was synthesized in transduced cells but
not in untransduced cells. As expected, b3 was detected in the
transduced and untransduced samples when the blot was
reprobed with an anti-b3 polyclonal antibody (Fig. 3 Lower).
Thus, provirus-derived b3 paired with the aIIb subunit to form
the aIIbb3 complex in the presence of endogenously derived
b3 in megakaryocyte progeny of CD341 cells.
FIG. 2. Analysis of PlA2b3 synthesis in transduced promegakaryo-
cytic (Dami) and epithelial (CFT1) cell lines. Immunoblot shows
PlA2b3 synthesis in Dami but not CFT1 cells. After cells were
transduced with 2889PlA2b3, 800 mg of each cell lysate (7.0 3 106
cells) was immunoprecipitated with a b3-specific mAb (AP3). The
complexed proteins were separated on a nonreduced SDS/ 8% PAGE
gel. PlA2b3 was detected (arrow) by using human anti-PlA2 alloimmune
serum and, chemiluminescence. Control represents untransduced cells
and LacZ are cells transduced with a retroviral vector encoding b-gal.
Molecular mass markers are shown in kDa (left).






















Transgene Expression Was Selectively Targeted to
Megakaryocyte Progeny of CD341 Cells by the aIIb Pro-
moter. To investigate the targeting specificity of the aIIb
promoter to megakaryocytes, CD341 cells were transduced
with an aIIb promoter-driven construct (2889nLacZ) encod-
ing the reporter gene, b-gal, and induced for 10 days to expand
and undergo megakaryocyte differentiation. The result was a
population of multilineage cells that included 20% megakaryo-
cytes expressing aIIbb3 (data not shown). Histochemical
analysis for b-gal activity was performed on these cells to
identify transgene expression, as illustrated in Fig. 4 a–c. The
aIIb promoter directed detectable expression of b-gal in cells
transduced with 2889nLacZ (Fig. 4b), whereas a tissue-
nonspecific promoter drove b-gal activity in a noticeably
greater population of cells transduced with CMVnLacZ (Fig.
4c). As a negative control for histochemical staining, b-gal
activity was not detected in untransduced cells (Fig. 4a). The
2889nLacZ-transduced cells were simultaneously stained for
b-gal activity and expression of the megakaryocyte-specific
marker, aIIbb3, to determine whether transgene expression
was selectively targeted to megakaryocyte progeny (Fig. 4 d–f ).
Expression of b-gal was detected in 94 of 1,173 total cells (8%)
transduced with 2889nLacZ (Fig. 5, hatched bar 3), and 63 of
1,173 cells (5%) simultaneously expressed aIIbb3 and b-gal
(Fig. 5, solid bar 3). Thus, 63 of the 94 cells expressing b-gal
(67%) were megakaryocytes in the 2889nLacZ-transduced
sample (Fig. 5, bar 3). In contrast, expression of b-gal was
identified in 327 of 1,759 total cells (19%) transduced with
CMVnLacZ (Fig. 5, hatched bar 1), whereas 105 of 1,759 total
cell (6%) simultaneously expressed aIIbb3 and b-gal (Fig. 5,
solid bar 1). Thus, only 105 of the 327 cells expressing b-gal
(32%) were megakaryocytes in the CMVnLacZ-transduced
sample (Fig. 5, bar 1). This difference in the capacity of the
aIIb promoter compared with the CMV promoter to selec-
tively target expression of b-gal to megakaryocytes (67% vs.
32%) was statistically significant with the x2 test (P 5 0.001).
The aIIb promoter limited expression of b-gal to a lower
percent of the total cell population than the CMV promoter
(8% vs. 19%), although '5% of the total cells simultaneously
expressed aIIbb3 and b-gal in both CMVnLacZ and
2889nLacZ-transduced samples, demonstrating that the pro-
moters were equal in their ability to drive transgene expression
in megakaryocytes (Fig. 5, solid bars 1 and 3).
FIG. 3. Analysis of PlA2b3 synthesis after transduction of human
CD341 cells. Immunoblot showing PlA2b3 synthesis in megakaryo-
cytes derived from transduced CD341 cells. Seventeen days after
transduction and differentiation, 850 mg of each cellular lysate was
immunoprecipitated with a aIIbb3 complex-specific mAb, AP2, and
detected with human anti-PlA2b3 alloimmune serum (Upper). The blot
reprobed with a polyclonal anti-b3 antibody demonstrates the pres-
ence of PlA1b3 in the untransduced Control sample (Lower). Molec-
ular mass markers are shown in kDa (left).
FIG. 4. b-gal targeted to megakaryocyte progeny of 2889nLacZ-transduced human CD341 cells. CD341 cells were transduced with a
MuLV-derived construct, 2889nLacZ, encoding b-gal and then induced to form megakaryocytes in culture. Histochemical staining was performed
after 10 days of differentiation to determine the percentage of the total cell population expressing b-gal. (a–c) b-Gal activity was detected in 0%
of untransduced cells (a), 8% of cells transduced with 2889nLacZ (b), and 19% of cells transduced with CMVnLacZ (c). (d–f ) The
2889nLacZ-transduced CD341 cells were simultaneously stained for b-gal activity and aIIbb3 expression to determine whether b-gal expression
was selectively targeted to progeny megakaryocytes. Arrows point to the same two cells unstained (d), stained for b-gal activity (e), and stained
for aIIbb3 ( f).






















The 2889nLacZ-transduced cells were examined by simul-
taneously staining for b-gal activity and expression of the
erythrocyte-specific marker, GPA, to determine whether the
aIIb promoter directed transgene expression in erythrocyte
progeny (Fig. 5, bars 2 and 4). Cells were induced for 12 days
to expand and differentiate into a cell population of multilin-
eages including 3% erythrocytes expressing GPA (data not
shown). When the tissue-nonspecific CMV promoter was used
to direct expression of b-gal, 167 of 761 total cells (22%) had
detectable b-gal activity (Fig. 5, hatched bar 2), and nearly 1%
of the total cells (4 of 761 cells) simultaneously expressed GPA
and b-gal (Fig. 5, solid bar 2). Interestingly, this meant that
14% of all erythrocytes (4 of 29 cells) identified expressed
b-gal in the CMVnLacZ sample (data not shown). Although
b-gal was expressed in 81 of 1,422 total cells (6%) transduced
with 2889nLacZ (Fig. 5, hatched bar 4), none of these cells
simultaneously expressed b-gal and the erythrocyte marker,
GPA. Likewise, 0 of 38 erythrocytes detected expressed b-gal.
This difference in b-gal expression in erythrocytes transduced
with aIIb promoter versus the CMV promoter (0% vs. 14%)
was statistically significant (Fisher’s exact test P 5 0.031).
Thus, the aIIb promoter remained silent in erythrocyte prog-
eny but active in the 2889nLacZ-transduced sample, whereas
the CMV promoter directed expression of b-gal in erythro-
cytes as well as megakaryocytes, demonstrating a difference in
the ability of each promoter to drive b-gal expression in
erythrocytes.
DISCUSSION
Lineage-specific expression of proteins is potentially impor-
tant for gene therapy of hematopoietic disorders affecting
distinct cell types (26). For example, indiscriminate expression
of the platelet-specific integrin, aIIbb3, in neutrophils, eryth-
rocytes, monocytes, or lymphocytes might alter the adhesive
properties of those cells, resulting in aberrant behavior that
could be detrimental (27). As a prelude to tissue-specific
human hematopoietic gene therapy, we used MuLV-derived
vectors under control of the promoter from aIIb, a gene
up-regulated during megakaryocyte differentiation (7), to
target synthesis of the integrin b3-subunit and b-gal to
megakaryocyte progeny of transduced CD341 cells. Our
results demonstrate that (i) MuLV LTR sequences do not
adversely affect the ability of the aIIb promoter to direct
transgene expression of b3 in a cell type-specific manner, (ii)
the aIIb promoter targeted transgene expression to
megakaryocyte progeny of transduced progenitor blood cells,
as evidenced by the formation of a hybrid aIIbb3 complex
consisting of endogenously derived aIIb-subunit and provirus-
derived b3, and (iii) the aIIb and CMV promoters equally
directed expression of b-gal in megakaryocyte progeny of
CD341 cells; however, the aIIb promoter had a statistically
increased ability to confine b-gal expression to megakaryo-
cytes. Based on these data, we conclude that aIIb promoter-
driven MuLV constructs selectively targeted transgene expres-
sion to megakaryocyte progeny of human CD341 cells. Like-
wise, we speculate that aIIb promoter targeted expression of
b3 in megakaryocytes derived from CD341 cells could have
therapeutic value for the platelet-bleeding disorder Glanz-
mann’s thrombasthenia.
aIIb promoter driven synthesis of b-gal was detected pri-
marily in megakaryocytes within a multilineage population
derived from CD341 progenitor cells. Because transduction of
CD341 cells with CMVnLacZ resulted in the expression of
b-gal in 20% of the cell population, and transduction with
2889nLacZ confined b-gal expression to 7% of the total cells,
we reasoned that the nearly 3-fold decrease in expression may
be explained by the CMV promoter’s ability to direct expres-
sion of the transgene in a lineage-nonspecific manner, whereas
b-gal expression under control of the aIIb promoter was
achieved primarily in cells that differentiated into megakaryo-
cytes. To test this hypothesis, we determined whether trans-
gene expression was targeted to megakaryocyte progeny by
simultaneously staining the cells for b-gal activity and expres-
sion of the megakaryocyte-specific marker aIIbb3. Our results
demonstrated that the aIIb promoter has an increased ability
compared with the CMV promoter to target transgene ex-
pression to megakaryocytes because 67% vs. 32% of all cells
expressing b-gal under control of the respective promoters also
displayed aIIbb3.
Evidence from in vivo studies with transgenic mice models
(5, 6) demonstrate that the aIIb promoter was activated
transiently in multilineage potential progenitor cells. Trans-
gene expression was maintained in the megakaryocyte progeny
and progressively turned off during erythroid and myeloid
lineage differentiation. Their observations suggest that our
detection of b-gal in cells not identified as megakaryocytes
may be potentially explained by a low-level up-regulation of
the aIIb promoter in multipotent hematopoietic progenitor
cells or in very early differentiating megakaryocytic, erythroid,
and myeloid cells. Based on this, we speculate that the 33% of
cells expressing b-gal in the absence of aIIbb3 in 2889nLacZ-
transduced samples are early megakaryocytes or multipotent
progenitors that express aIIbb3 at subdetectable levels with
the relatively insensitive immunofluorescence analysis but
stain positive for b-gal with a sensitive enzymatic assay.
Because megakaryocytes and erythrocytes are derived from
a common precursor cell, we investigated aIIb promoter-
driven b-gal expression in erythrocytes derived from trans-
duced CD341 cells by simultaneously staining the cells for
b-gal activity and expression of the erythrocyte-specific
marker GPA. b-Gal was not detected in erythrocytes after
2889nLacZ transduction of CD341 cells, providing support
for the contention that retrovirus-mediated transgene expres-
sion driven by the aIIb promoter was not leaky. In contrast,
transgene synthesis driven by the CMV promoter, a lineage-
nonspecific promoter, was evident in megakaryocytes as well
as erythrocytes.
FIG. 5. A stacked bar graph demonstrating the difference in aIIb
and CMV promoter-targeted transgene expression to megakaryocyte
and erythrocyte progeny of transduced CD341 cells. Human CD341
cells were transduced with MuLV-derived constructs, CMVnLacZ
(bars 1 and 2) and 2889nLacZ (bars 3 and 4) and then induced to
expand and differentiate into a multilineage cell population. Histo-
chemical staining was performed after 10 days of differentiation to
determine the percent of the total cell population expressing b-gal for
each promoter (hatched bars). The cells were simultaneously stained
for b-gal activity and expression of the megakaryocyte-specific
marker, aIIbb3 (solid bars 1 and 3) or the erythrocyte-specific marker,
GPA (solid bars 2 and 4) and scored to determine whether b-gal
expression was selectively targeted to megakaryocytes. In a negative
control, b-gal was not detected in untransduced cells. The results are
from a single experiment that is representative of two experiments.






















The strategy to transduce CD341 cells followed by their
induction to differentiate along the megakaryocytic pathway in
vitro was chosen to parallel strategies that might be applicable
for human gene therapy in vivo (8). Because terminally dif-
ferentiated megakaryocytes, leukocytes, and erythrocytes
have limited lifespans, genetic material must be transferred
into the self-replicating pool of stem cells to maintain long-
term transgene expression. Small animals have been trans-
planted with an engrafting population of human CD341 cells
that have sustained long-term transgene expression into the
progeny cells (28). Confusingly, only short-term transgene
expression has been achieved when CD341 cells are trans-
planted into humans. This may be partially because of an
immune response to stem cells expressing a transgene under
the control of a tissue-nonspecific promoter. Likewise, stem
cells transduced with a MuLV construct under control of the
aIIb promoter may avoid elimination by the immune system
and sustain long-term transgene expression that is not acti-
vated until derived pluripotent progenitor cells commit to
megakaryocytopoiesis. Short-term transgene expression in
humans may also be due to a low efficiency of transduction into
the stem cell population necessary for reconstituting the
human hematopoietic system. We observed a moderate effi-
ciency of transduction into CD341 cells with the detection of
aIIb promoter-driven transgene expression in 63 of 310 de-
rived megakaryocytes (20%); however, the potential useful-
ness of this MuLV vector for human gene therapy remains to
be determined in vivo. Although MuLV-derived vectors have
a limited capability to transduce the slow-dividing pool of stem
cells, the aIIb promoter may alternatively be used in other
gene-transfer systems [i.e., adeno-associated virus type 2 (12)
or lentivirus (29, 30)] that can transduce nondividing cells with
greater efficiency than MuLV.
The capacity to target expression of heterologous gene
products to megakaryocyte progeny of CD341 cells presents
a variety of possible applications. First, signaling and other
molecules or their activators may be expressed in megakaryo-
cytes to examine the effect on cytoskeletal development and
receptor activation (31). Second, modulation of the activat-
ability of multiple-subunit receptors like aIIbb3 of
megakaryocytes may be achieved by targeting expression of
abnormal subunits (b3) that can complex with their normal
counterparts (aIIb) to study the result on receptor function
(32). Third, megakaryocyte-targeted expression of dominant-
negative gene products may be performed to observe the
consequence of inhibited synthesis of growth factors, mem-
brane receptors, and signaling molecules on platelet develop-
ment and function. These three applications may be studied in
vitro and have the potential to be assessed in vivo by infusion
of transduced cells into animal models to examine the effect of
the altered platelets on physiological processes such as primary
hemostasis and wound healing in addition to pathophysiologic
events leading to atherogenesis, thrombogenesis, and throm-
bocytopenia. Finally, this technology was developed for its
potential use for human gene therapy of platelet disorders and
may allow platelets to deliver other therapeutic agents to the
site of a vascular injury.
This investigation was supported by Grant HL-45100 (to G.C.W.)
from the National Institutes of Health and by an American Heart
Association (North Carolina Affiliate) Postdoctoral Fellowship Award
NC-95-FW-63 (To D.A.W.).
1. Romeo, P. H., Prandini, M. H., Joulin, V., Mignotte, V., Prenant,
M., Vainchenker, W., Marguerie, G. & Uzan, G. (1990) Nature
(London) 344, 447–449.
2. Fong, A. M. & Santoro, S. A. (1994) J. Biol. Chem. 269,
18441–18447.
3. Prandini, M. H., Martin, F., Thevenon, D. & Uzan, G. (1996)
Blood 88, 2062–2070.
4. Block, K. L., Ravid, K., Phung, Q. H. & Poncz, M. (1994) Blood
84, 3385–3393.
5. Tronik-Le Roux, D., Roullot, V., Schweitzer, A., Berthier, R. &
Marguerie, G. (1995) J. Exp. Med. 181, 2141–2151.
6. Tropel, P., Roullot, V., Vernet, M., Poujol, C., Pointu, H.,
Nurden, P., Marguerie, G. & Tronik-Le Roux, D. (1997) Blood
90, 2995–3004.
7. Uzan, G., Prandini, M. H. & Berthier, R. (1995) Thromb Haemost
74, 210–212.
8. Choi, E. S., Nichol, J. L., Hokom, M. M., Hornkohl, A. C. &
Hunt, P. (1995) Blood 85, 402–413.
9. Newman, P. J., Allen, R. W., Kahn, R. A. & Kunicki, T. J. (1985)
Blood 65, 227–232.
10. Pidard, D., Montgomery, R. R., Bennett, J. S. & Kunicki, T. J.
(1983) J. Biol. Chem. 258, 12582–12586.
11. Olsen, J. C., Johnson, L. G., Stutts, M. J., Sarkadi, B., Yankaskas,
J. R., Swanstrom, R. & Boucher, R. C. (1992) Hum. Gene Ther.
3, 253–266.
12. Bartlett, J. S., Sethna, M., Ramamurthy, L., Gowen, S. A.,
Samulski, R. J. & Marzluff, W. F. (1996) Proc. Natl. Acad. Sci.
USA 93, 8852–8857.
13. Heidenreich, R., Eisman, R., Surrey, S., Delgrosso, K., Bennett,
J. S., Schwartz, E. & Poncz, M. (1990) Biochemistry 29, 1232–
1244.
14. Goldberger, A., Kolodziej, M., Poncz, M., Bennett, J. S. &
Newman, P. J. (1991) Blood 78, 681–687.
15. Faustinella, F., Kwon, H., Serrano, F., Belmont, J. W., Caskey,
C. T. & Aguilar-Cordova, E. (1994) Hum. Gene Ther. 5, 307–312.
16. Johnson, L. G., Mewshaw, J. P., Ni, H., Friedmann, T., Boucher,
R. C. & Olsen, J. C. (1998) J. Virol. 72, 8861–8872.
17. Skogen, B., Bellissimo, D. B., Hessner, M. J., Santoso, S., Aster,
R. H., Newman, P. J. & McFarland, J. G. (1994) Transfusion 34,
955–960.
18. Olsen, J. C. & Sechelski, J. (1995) Hum. Gene Ther. 6, 1195–1202.
19. Rowley, S. D., Loken, M., Radich, J., Kunkle, L. A., Mills, B. J.,
Gooley, T., Holmberg, L., McSweeney, P., Beach, K., MacLeod,
B., et al. (1998) Bone Marrow Transplant. 21, 1253–1262.
20. Moritz, T., Dutt, P., Xiao, X., Carstanjen, D., Vik, T., Hanenberg,
H. & Williams, D. A. (1996) Blood 88, 855–862.
21. Kimizuka, F., Taguchi, Y., Ohdate, Y., Kawase, Y., Shimojo, T.,
Hashino, K., Kato, I., Sekiguchi, K. & Titani, K. (1991) J. Bio-
chem. (Tokyo) 110, 284–291.
22. Hanenberg, H., Xiao, X. L., Dilloo, D., Hashino, K., Kato, I. &
Williams, D. A. (1996) Nat. Med. 2, 876–882.
23. Bartley, T. D., Bogenberger, J., Hunt, P., Li, Y. S., Lu, H. S.,
Martin, F., Chang, M. S., Samal, B., Nichol, J. L., Swift, S., et al.
(1994) Cell 77, 1117–1124.
24. Wilcox, D. A., Wautier, J. L., Pidard, D. & Newman, P. J. (1994)
J. Biol. Chem. 269, 4450–4457.
25. Uzan, G., Prenant, M., Prandini, M. H., Martin, F. & Marguerie,
G. (1991) J. Biol. Chem. 266, 8932–8939.
26. Dzierzak, E. A., Papayannopoulou, T. & Mulligan, R. C. (1988)
Nature (London) 331, 35–41.
27. Chen, Y. Q., Trikha, M., Gao, X., Bazaz, R., Porter, A. T., Timar,
J. & Honn, K. V. (1997) Int. J. Cancer 72, 642–648.
28. Plavec, I., Voytovich, A., Moss, K., Webster, D., Hanley, M. B.,
Escaich, S., Ho, K. E., Bohnlein, E. & DiGiusto, D. L. (1996)
Gene Ther. 3, 717–724.
29. Olsen, J. C. (1998) Gene Ther. 5, 1481–1487.
30. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage,
F. H., Verma, I. M. & Trono, D. (1996) Science 272, 263–267.
31. Defilippi, P., Venturino, M., Gulino, D., Duperray, A., Boquet,
P., Fiorentini, C., Volpe, G., Palmieri, M., Silengo, L. & Tarone,
G. (1997) J. Biol. Chem. 272, 21726–34.
32. Wang, R., Shattil, S. J., Ambruso, D. R. & Newman, P. J. (1997)
J. Clin. Invest. 100, 2393–2403.
Cell Biology: Wilcox et al. Proc. Natl. Acad. Sci. USA 96 (1999) 9659
D
ow
nl
oa
de
d 
by
 g
ue
st
 o
n 
F
eb
ru
ar
y 
5,
 2
02
1 
